Makoto Yamamoto

Founder & CEO | TKG Therapeutics Inc. Leading the development of next-generation cancer therapeutics based on a proprietary nucleic acid platform utilizing dual hairpin DNA molecules. This technology is triggered by onco-miRs to self-assemble within cancer cells, inducing programmed cell death and activating antitumor immune responses. Overseeing the entire pipeline—from proof-of-concept validation and GMP-grade oligonucleotide manufacturing to clinical translation—while driving strategic collaborations with pharmaceutical partners and academic institutions to advance innovative oncology therapeutics.

Lead & Product Manager, New Business Development Division Led new business initiatives in IoT-based healthcare solutions for dogs and cats, building a data-driven preventive medicine platform. Directed the end-to-end design and development of wearable activity trackers and mobile apps, coordinating over ten partner companies, academic collaborations, and veterinary networks. Achieved 10,000+ device sales and partnerships with 1,150 veterinary clinics nationwide. The project raised ¥24.5M—the highest in PetTech crowdfunding history—and won the Impress DX Awards 2019 (Runner-up). Later, served as Product Manager for a non-contact vital monitor using Doppler sensors, enabling continuous measurement of heart rate, respiration, and movement in animals. Successfully deployed to 250+ veterinary hospitals, driving operational efficiency and digital transformation in clinical settings.

Program Manager, Kyoto University Incubation Program Served as Business Development Lead in a Kyoto University incubation program, advancing a project to develop additives for organ preservation solutions. Collaborated directly with the principal investigator to integrate scientific and commercial strategies. Oversaw research–business meetings, regulatory planning, and market analysis in Japan and the US. Designed a strategy to pursue FDA approval prior to PMDA submission, addressing Japan’s pricing limitations. Led coordination with US–Japan regulatory consultants and academic partners, maintaining effective communication and progress across time zones. Drove the project from research phase toward preclinical development through structured and globally coordinated management.

アカデミア創薬、知財戦略に関する講義を定期的に実施していました。

As a Senior Research Scientist at KinoPharma, led the development of a novel antiviral drug based on an unexplored mechanism of action. Managed in vitro/in vivo studies, formulation, and preclinical planning, resulting in a candidate that progressed to clinical trials. Discovered the target protein through genomic and proteomic analysis in collaboration with the University of Tokyo and the University of Kyoto, leading to a first-author paper in J Clin Invest. (2014, IF 13.2) and a national scientific award. Filed global patents (PCT) and coordinated preclinical studies in Japan and Korea, building strong relationships with CRO partners.

At the Tokai University Institute of Medical Science, engaged in the development of a novel peritoneal dialysis device based on a unique mechanism of action. Developed high-affinity adsorption beads that suppress carbonyl stress and improve the safety of PD fluid, achieving proof-of-concept efficacy superior to conventional methods. Responsibilities included exploring novel mechanisms, conducting in vitro/in vivo pharmacological studies, and authoring a first-author paper (Perit Dial Int., 2007). Collaborated closely with industry and international researchers, strengthening research coordination and communication skills.